FDA Adcomm Votes in Favor of Rexulti for Agitation in Alzheimer’s

Lundbeck and Otsuka anticipate a favorable decision from the FDA after Adcomm voted 9–1 to add agitation in Alzheimer’s indication to the Rexulti label.